Join us for another insightful episode of The Oncology Brothers as we dive into the Challenging Case Series! In this episode, we were joined by Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, to discuss the complexities of treating EGFR-positive non-small cell lung cancer (NSCLC). We explored the latest treatment options, including:•⁠  ⁠Osimertinib•⁠  ⁠Amivantamab plus Lazertinib (based on the MARIPOSA trial)•⁠  ⁠Osimertinib plus chemotherapy (from the FLAURA2 trial) Listen in as we analyze real-life patient cases, focusing on a 58-year-old gentleman with CNS involvement and a 66-year-old woman experiencing disease progression after initial treatment. Dr. Singhi shared valuable insights on the importance of supportive care, the impact of treatment combinations, and the significance of repeat tissue profiling. Key topics covered:•⁠  ⁠The latest data from the MARIPOSA and FLAURA2 trials•⁠  ⁠Strategies for managing side effects and improving patient quality of life•⁠  ⁠The role of multidisciplinary teams in treatment planning•⁠  ⁠The importance of understanding resistance patterns in treatment decisions Whether you're a healthcare professional or simply interested in oncology, this episode is packed with essential information and expert perspectives.  Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from The Oncology Brothers! #EGFRNSCLC #Mariposa #Amivantamab #Osimertinib #FLAURA2 #OncologyBrothers #LungCancer